1. INTRODUCTION {#sec1-1}
===============

Cardiovascular diseases (CVD) are generally believed as a major concern responsible for human mortality while being among the foremost causes of preventable death ([@ref1], [@ref2], [@ref3], [@ref4]). Atherosclerosis is the major reason of cardiovascular diseases and is an important cause of arterial wall disorder which directly influences large and medium-sized arteries. Different factors contribute to atherosclerosis; but dyslipidemia seems to be an important contributor. Elevated low density lipoprotein cholesterol (LDL) and reduced high density lipoprotein cholesterol (HDL) levels were previously known risk factors for developing atherosclerosis ([@ref2], [@ref5], [@ref6]).

Obesity, as an important cause of CVDs, is associated with diverse cardiovascular disease risk factors like hypertension, dyslipidemia, escalated insulin levels and finally an increased risk of CVD morbidity and mortality in adulthood ([@ref3], [@ref7]). Modification of some socioeconomic behavioral habits like smoking, alcohol consumption, dietary patterns and physical activity especially from childhood and adolescence is important and effective measures for the prevention of CVDs ([@ref8], [@ref9]).

Albeit the clinical emergencies of atherosclerosis are displayed in adulthood, early atherosclerotic changes are apparent in youth studied post-mortem. Thus, effective prevention of atherosclerosis is advised to be started in childhood or adolescence ([@ref4], [@ref10], [@ref11], [@ref12], [@ref13]).

On the other hand the increasing prevalence of childhood obesity is a worldwide trend and is becoming globally a remarkable public health problem. A decline in physical activity and an increase in amount of calorie intake may be responsible for this increasing incidence. Hence, lifestyle modification and weight control in childhood should be noticed enough to reduce the risk of CVD in adulthood ([@ref7], [@ref14], [@ref15], [@ref16], [@ref17]).

Various chemical and herbal types of medications are used nowadays for the prevention and treatment of hyperlipidemia Statins and fibrates are the most common chemicals used to treat plasma lipid disorders; however concerns about their side effects like elevation of liver enzymes, gastrointestinal symptoms, predisposition to cholelithiasis, rhabdomyelosis, myopathy, renal dysfunction, etc and also lack of general agreement about their use in children and adolescents, have persuaded the scientists to find an appropriate substitution for them ([@ref11], [@ref15], [@ref18], [@ref19]).

Different studies have showed herbal drugs in treatment of dyslipidemia and prevention of LDL-oxidation thanks to their constituents like dietary fibers, vitamins, flavonoids, estrols, polyphenols, antioxidant compounds, etc as invaluable sources. Although these effects are weaker than chemical drugs, their use in primary stages of dyslipidemia and atherosclerosis seems rational ([@ref11], [@ref20], [@ref21]).

*Hibiscus sabdariffa* L. \[Roselle\] is a plant which belongs to the Malvaceae family and is widely cultivated in the tropical areas like Caribbean, Australia, Brazil, Central America, India, Africa, US and Philippines. This plants is used from times as a traditional medicine due to its effects against kidney stones and urinary bladder stones, and also its antibacterial, antifungal, hypocholesterolemic, antispasmodic and antihypertensive effects. It is used as a folk medicinal plant in Iran and has been recognized as sour tea ([@ref22], [@ref23]).

*H. sabdariffa* L. is rich in polyphenols, anthocyanins, flavonoids that may justify its use in prevention of cardiovascular disorders. According to the antioxidant and antilipid peroxidation actions of *Hibiscus* extract, it is considered that *Hibiscus* anthocyanins and procatechuic acid may also have a role in amelioration or prevention of these clinical conditions ([@ref24], [@ref25]). The aim of this study a study was to evaluate the effect of Hibiscus sabdariffa calices on dyslipidemia in obese adolescents.

2. METHODS {#sec1-2}
==========

Study design {#sec2-1}
------------

This randomized triple masked placebo controlled clinical trial was conducted from July 2010 to July 2011 in Isfahan cardiovascular research institute, Isfahan (Iran) and registered in the Iranian registry for clinical trials (IRCT201109122306N2). Ninety (n=90) school-age adolescents (12 to 18 years old) who had at least one of these criteria: a) serum triglyceride more than 90 percentile b) serum total cholesterol more than 90 percentile c) LDL more than 90 percentile d) HDL less than 10 percentile, not using tobacco, no history of alcohol consumption or drug abuse, no history of metabolic diseases like diabetes, thyroid gland dysfunction, nephrotic syndrome, chronic pancreatitis, liver and gall bladder diseases and no drug consuming (which affects lipid profiles like statins and hormonal pills like estrogens, progestrones and oral contraceptives) were screened for inclusion in the study. Exclusion criteria were lack of patients' compliance with drug regimens at least for one week, pregnancy and lactation, drug sensitivity, presence of any disease which could interact with lipid profiles and need to take of any kind of drugs or other compounds which affects lipid profile like corticosteroids, androgens, estrogenes, progestines, thiazides, beta blockers and thyroid hormones . The study was approved by the institutional ethics committee of Isfahan Medical University of sciences and all participants and their parents or guardians read and signed a written informed consent form before participation ([@ref26], [@ref27], [@ref28]).

Sample size was determined according the t-student formula. Accordingly the most important variable in this study was considered as serum level of cholesterol which is a quantitative continuous variable and to detect at least 10 mg/dl decrease of this variable in case group (comparing to the controls), with 80% power and 5% type 1 error, suitable sample size was calculated 35 people in each group. To rectify anticipating losses of patients in terminating treatment period, sample size was expanded by 20%. The participants divided into two groups of case and control using table of random numbers.

A registered dietitian explained the same protocols for physical activity and food regimen for both groups. Lipid parameters, fasting blood sugar and thyroid hormone measured before study to screen for eligible participants for the study. Patients took 6 grams of powders per day (placebo or drug in identical packages) in divided doses for a complete 4 weeks period and the adherence to the therapy were checked after two weeks in the middle of study period for each patient separately. All lipid profile indicators and anthropometric factors were measured after the study period as well.

Collection and preparation of blood samples {#sec2-2}
-------------------------------------------

All fasting blood samples were taken in the morning between 7:00 and 9:00 am. Venous blood samples obtained after eight hours of fasting and blood samples were frozen for a maximum of two weeks and stored at -70 C° until the time of biochemical analysis. Serum cholesterol levels were measured by enzymatic colorimetric methods using commercial kits obtained from Parsazmoon (Karaj, Iran).

Preparing the dosage form {#sec2-3}
-------------------------

*H. sabdariffa* L. was bought from Isfahan (Iran) medicinal plant market and air dried *H. sabdariffa* L. calices were blended into fine powder and then packaged into 2 gram sachets.

Polyphenol content of plant determined using folin-ciocalteu method. 1 gram of powder was added to 100 ml water and refluxed until water boiled. Then the extract was filtered and 1ml of that was diluted with distilled water to 100 ml. Thereafter 20 µl of this solution poured into a test tube and 1.58 ml water and100 ml folin-ciocalteu reagent added and mixed for 5 minutes and then 300 ml of super-saturated sodium bicarbonate solution added. After two hours in room temperature, mixture absorbance measured in 765 nm using a spectrophotometer (Jenway 6105, Staffordshire, UK). A standard curve of Gallic acid was prepared as well ([@ref29]).

Statistical analysis {#sec2-4}
--------------------

The data are presented as Mean ± SD. A Kolmogrov-smirnov test was performed to show normal distribution of all measured data. An independent t-test analysis was performed to verify whether significant differences existed between the anthropometric and biochemical parameters of the subjects in the cases and controls groups at the baseline. Chi-square test used to compare gender variable in cases and controls groups. The paired samples t-test was used to compare differences between subjects of each group before and after the study. A multivariate general linear model test was performed to assess the changes over the time in the anthropometric and biochemical parameters between the two groups and also to offset the effect of confounding factors like age, gender and body mass index (BMI). The level of significance was considered as 0.05.

3. RESULTS {#sec1-3}
==========

The total polyphenolic content of *H. sabdariffa* L. calyx after triple measurement was equivalent to 16.4 milligram Gallic Acid per gram. A total of 90 eligible volunteers were recruited for the study and 7 participants from the cases and 11 from the controls group dropped out of the study due to irregular consumption of drugs, changing usual diet or irregular attendance for measuring lipid profiles. Finally 36 people completed the study in each group ([Figure 1](#fig001){ref-type="fig"}).

The mean age of the subjects in the cases was 14.17±1.61 years and 14.25±1.59 years in the controls. There were no statistically difference in the mean age (p=0.826), gender (p=0.907), body mass index (p=0.648) and lipid profile between the cases and controls before the study. Demographic data of all participants (age, gender and body mass index) are summarized in [Table 1](#table001){ref-type="table"}.

Lipid profile outcomes before and after treatment in cases and controls are shown in Table-2. The data showed a significant decrease in LDL, total cholesterol and triglyceride in cases (without any significant decrease in HDL). The p value results of the multivariate general linear model analysis of lipid profiles for triglyceride, total cholesterol, LDL and HDL were 0.01, 0.032, 0.005 and 0.782 respectively. This information reveals noticeable decrease in triglyceride, total cholesterol and LDL and no significant decrease in HDL ([Table 2](#table002){ref-type="table"}). In this study no significant drug side effects was reported except some mild gastrointestinal symptoms (e.g. temporary constipation).

4. DISCUSSION {#sec1-4}
=============

Considering the increasing need to find effective cholesterol lowering agents and the role of diet in reducing atherosclerosis risk, edible plants are markedly being considered as a resources of anti atherosclerosis agents ([@ref30]). Recently, many clinical studies proposed dyslipidemia as one of the major risk factors for coronary disease. Preclinical observations demonstrate that hypercholesterolemia aggregates accumulation of oxidized Low-density lipoprotein (Ox-LDL) in the arterial wall, promoting endothelial cell dysfunction and therefore promotion of atherosclerosis ([@ref24], [@ref31]).

*H. sabdariffa* L., an annual herbaceous shrub, is a traditional chinese rose tea, cultivated in tropical areas like Africa, Asia and Central America used effectively in folk medicine. The chemical constituents reported in this plant are phenolic compounds, anthocyanins, flavonoids, protocatechuic acid, Vitamin C and carotenoid ([@ref23], [@ref24], [@ref32], [@ref33]). Different studies have showed variety of pharmacologic actions of this plant like antioxidative, antimutagenic, anticancer, hypolipidemic and liver protective ([@ref24], [@ref32], [@ref34]-[@ref36]). Some studies on the cholesterol lowering effect of *H. sabdariffa* L. have previously been conducted on animals and humans ([@ref24], [@ref37], [@ref38]).

In a study conducted to establish the effect of anthocyanins content of *H. sabdariffa* L., it was observed that extracts of *Hibiscus* flowers prevents LDL oxidation and macrophage death ([@ref39]). Another investigation about effects of *H. sabdariffa* L. extract powder and preventive diet in patients with metabolic syndrome showed antihypertensive and antihyperlipidemic impacts for this plant ([@ref40]). Another study revealed that the aqueous extract of *H. sabdariffa* L. calices modulates the production of monocyte chemoattractant protein-1 in humans and lower production of mcp1, which means the slower development of atherosclerosis ([@ref41], [@ref42]). Also another study proved the effect of anthocyanin extracted from *Hibiscus* in attenuating oxidized LDL-mediated foam cell formation involving regulation of CD36 gene ([@ref43]).

According to statistical data in cases and controls before and after consumption of *H.s sabdariffa* L. powder and placebo, the results show that using up the plant for one month decreases serum total cholesterol, triglyceride and LDL effectively. Meanwhile, LDL downturn (p=0.005) by 7% fall and triglyceride downward trend (P=0.01) by 9% fall show more prominent decline in comparison with other parameters; hence it shows the noticeable capacity of this herbal plant in modifying serum LDL and triglyceride. The short period of drug usage (a one month period) may justify the ineffectiveness of the plant on HDL, and longer exposures to the drug may be needed to have a more accurate conclusion.

5. CONCLUSION {#sec1-5}
=============

It is concluded that *H. sabdariffa* L. due to its polyphenolic and antioxidant compounds may have positive effects on serum lipids profile and presumably can be considered for future studies on prevention and treatment of dyslipidemia and atherosclerotic disorders in adolescents.
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###### 

Demographic data of the study patients

  Groups     Number of patients (n)   Gender   Average age (years ± SD)   Body Mass Index   
  ---------- ------------------------ -------- -------------------------- ----------------- -------
             36                       Boys     Girls                                        
  Cases      36                       19       17                         14.17±1.61        25.66
  Controls   36                       16       20                         14.25±1.59        25.11

###### 

Lipid profile data of study patients before and after consuming 2 grams of fine powder of H. sabdariffa calices

  Groups                                                       Cholesterol (mg/dl)   Triglyceride (mg/dl)   LDL[\*\*](#tfn002){ref-type="table-fn"} (mg/dl)   HDL[\*](#tfn001){ref-type="table-fn"} (mg/dl)   
  ------------------------------------------------------------ --------------------- ---------------------- ------------------------------------------------- ----------------------------------------------- ------------
  Cases                                                        before                186.5±30.42            146±49.87                                         111.36±24.54                                    45.64±8.59
  After                                                        176.11±23.1           134.22±50.17           103.36±21.94                                      43.17±7.77                                      
  Controls                                                     before                200.6±43.59            166.17±44.42                                      125.28±37.75                                    41.58±9.77
  After                                                        198.5±43.12           163.44±43.64           124.17±36.76                                      42.17±9.52                                      
  Statistical analysis[\*\*\*](#tfn003){ref-type="table-fn"}   Case                  P=0.003                P=0.022                                           P\<001                                          P=0.057
  control                                                      P=0.1                 P=0.052                P=0.097                                           P=0.649                                         

\* High Density Lipoprotein,

\*\* Low Density Lipoprotein,

\*\*\* Paired-Samples T test
